Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Phase 3

Completed

• Conditions: Urinary Tract Infection
• Interventions: Drug: Canephron® N; Drug: Fosfomycin trometamol; Drug: Canephron® N-placebo; Drug: Fosfomycin trometamol-placebo

• Registration Number: NCT02639520
• Lead Sponsor: Bionorica SE

Brief Summary

To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.

Detailed Description

The trial is designed as a comparison of two different modes of action in order to look for alternatives to antibiotic treatment of uncomplicated UTIs. Treatment with CLR is a nonantibiotic therapy and is compared to an antibiotic treatment. Thus, the trial aim is to reduce antibiotics use and moreover to reduce the pressure of developing bacterial resistance against antibiotics due to widespread use, which is an additional advantage of the CLR therapy.

The trial results are expected to demonstrate that antibiotic prescriptions in women for treatment of lower uUTIs can be reduced by an alternative and safe non-antibiotic treatment.

Study Timeline

• Study Start: 2015-12
• Study First Submitted: 2015-12-11
• Study First Submitted QC: 2015-12-21
• Study First Posted: 2015-12-24
• Primary Completion: 2017-06
• Study Completion: 2017-06-29
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-26
• Last Update Posted: 2017-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 659

Inclusion Criteria

1. Signed informed consent (IC) and data protection declaration
2. Female outpatients aged 18 to 70 years
3. Sum-score of the main uUTI symptoms (dysuria, pollakisuria, and urgency) reported on the Acute Cystitis Symptom Score (ACSS)-"Typical" domain at Visit 1 is ≥6
4. Symptoms of the acute episode of lower uUTI are developed within not more than 6 days prior to Visit 1
5. Leukocyturia at Visit 1, confirmed by positive dipstick
6. Patients willing to refrain from consuming prohibited concomitant medications and products
7. Non-lactating female patients who are surgically sterile (have had a documented sterilization, bilateral oophorectomy at least 3 months before the start of the trial and/or hysterectomy), or postmenopausal (cessation of menses for at least 12 months), or women of childbearing potential with a negative pregnancy test at Visit 1 willing to use highly effective (failure rate less than 1% per year, i.e., Pearl Index <1) contraception methods, e.g., contraceptive patch, oral, injected or implanted hormonal methods of contraception, during the trial including the follow-up period.

Exclusion Criteria

1. Any signs of complicated urinary tract infections (UTIs), pyelonephritis (i.e., fever T ≥38.0°C [grade 2], flank and/or back pain, chills and shivers), and/or vulvo-vaginitis with vaginal and/or with urethral discharge (without urination) at Visit 1.
2. Any conditions that may lead to complicated infections (i.e., renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, uncontrolled diabetes mellitus, spinal cord injury, etc.).
3. Chronic infection of the urinary tract known from medical history.
4. Persisting signs or symptoms of severe, progressive, or uncontrolled systemic disease (i.e., renal, hepatic, biliary, hematological, gastro-intestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease).
5. Uncontrolled hypertension (a diastolic blood pressure >95 mmHg at Visit 1).
6. Known severe cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at Visit 1.
7. Any antibiotic therapy within 30 days prior to Visit 1.
8. Other acute infections (except uUTIs) requiring antibiotic treatment at Visit 1.
9. Patients receiving treatment for suspected or confirmed UTI (antibiotic or phytopharmaceutical) within 30 days prior to Visit 1.
10. Patients who took anti-inflammatory drugs (e.g., ibuprofen) or spasmolytics for any reason within 24 hours prior to Visit 1, and/or are not willing to stop the intake of any of the medication not permitted for use during the trial.
11. Known severe impaired renal function (creatinine clearance <20 mL/min).
12. Active peptic ulcers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group Fosfomycin Trometamol	Canephron® N-placebo	Canephron® N-placebo \& fosfomycin trometamol
Group Canephron® N	Canephron® N	Canephron® N \& fosfomycin trometamol-placebo
Group Canephron® N	Fosfomycin trometamol-placebo	Canephron® N \& fosfomycin trometamol-placebo
Group Fosfomycin Trometamol	Fosfomycin trometamol	Canephron® N-placebo \& fosfomycin trometamol

Primary Outcome Measures

Name	Time	Method
Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4	within 38 days after Visit 1 (=day 1)	For patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a "treatment failure" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.; The primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).

Trial Locations

Locations (1)

Justus-Liebig-Universität; 🇩🇪 Giessen, Hessen, Germany